A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Summary

This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Overweight
• Obesity

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

8 to 18 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Novo Nordisk A/S

Last updated on ClinicalTrials.gov

September 30, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites